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Due to their very good chemical and proteolytic stability, ability to penetrate cell membranes, and resemblance to a peptide 
bond, carbamate derivatives have received much attention in recent years and got an important role in modern drug 
discovery and medicinal chemistry. Today, carbamates make structural and/or functional part of many drugs and prodrugs 
approved and marketed for the treatment of various diseases such as cancer, epilepsy, hepatitis C, HIV infection, and 
Alzheimer’s disease. In drugs they can play a role in drug-target interaction or improve the biological activity of parent 
molecules. In prodrugs they are mainly used to delay first-pass metabolism and enhance the bioavailability and effectiveness 
of compounds. This brief review takes a look at the properties and use of carbamates in various fields of medicine and 
provides quick insights into the mechanisms of action for some of them.
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Carbamates are derivatives of carbamic acid, whose 
amino and carboxyl termini are substituted by a variety of 
structurally diverse alkyl, aryl, or alkyl-aryl substituents 
and are identified by the presence of the -O-CO-NH- linkage 
(1). Carbamates are integral part of many drugs and 
prodrugs approved by the US Food and Drug Administration 
(FDA) and the European Medicines Agency (EMA). Many 
compounds that contain a carbamate group are currently in 
various stages of preclinical and clinical trials (1, 2). An 
example of a carbamate compound recently approved by 
the FDA is cenobamate (3), indicated for the treatment of 
partial-onset seizures in adults (4).
The research of carbamates as potential drugs began 
with the discovery of physostigmine, a methyl carbamate 
ester isolated in pure form from the seeds of Calabar beans 
(Physostigma venenosum) in 1864 (5). Initially, 
physostigmine was used to treat high eye pressure and 
glaucoma, but today, it is also used to treat delayed gastric 
emptying and myasthenia gravis (5, 6). Broader utilisation 
of carbamate compounds began in 1959, when carbaryl was 
registered as first carbamate pesticide for use in the USA 
(5). Today, carbamate compounds are widely used as 
pesticides (insecticides, fungicides, and herbicides), as 
starting materials in the production of paints and 
polyurethanes, and as protecting groups of amines in organic 
synthesis (7).
Studies have shown that the carbamate group increases 
the biological activity of active pharmacophores of 
structurally different natural or synthesised compounds (7, 
8). By varying the substituents at the amino and carboxyl 
termini of the carbamate group, it is possible to modulate 
their biological and pharmacokinetic properties and 
improve their stability (7, 8).
The chemical properties of carbamates, their 
conformational and metabolic stability, the ability to pass 
through cell membranes, and some through the blood-brain 
barrier, have made the carbamate group a desirable part of 
the structure of many pharmacologically important 
compounds and a structural motif of many drugs and 
prodrugs.
Moreover, strong growth of carbamate use in the 
pharmaceutical industry is additionally boosted by the fact 
that the carbamate group can be considered a structural 
analogue of the amide bond (8–10). Amide-based molecules 
make a very good starting point for developing many drugs, 
enzyme inhibitors in particular. However, their inadequate 
pharmacokinetic properties, most notably poor in vivo 
stability and low bioavailability, limit their broader use and 
development. These limitations of amide-based compounds 
have recently been addressed by the use of carbamates as 
amido- or peptidomimetics to improve drug potency, 
duration of action, or target specificity (2, 9–11).
Today, the carbamate group makes part of many 
approved drugs which act as chemotherapeutic agents 
(mitomycin C, irinotecan), cholinesterase inhibitors in the 
treatment of neurodegenerative disorders (rivastigmine, 
neostigmine, physostigmine, pyridostigmine), human 
immunodeficiency virus (HIV) protease inhibitors 
(r i tonavir,  amprenavir,  atazanavir,  darunavir) , 
anticonvulsants (felbamate, retigabine, cenobamate), 
a n t h e l m i n t i c s  ( f e b e n d a z o l e ,  a l b e n d a z o l e , 
Corresponding author: Anita Bosak, Institute for Medical Research and 
Occupational Health Ksaverska cesta 2, 10000 Zagreb, Croatia
E-mail: abosak@imi.hr
Matošević A, Bosak A. Carbamate group as structural motif in drugs: a review of carbamate derivatives used as therapeutic agents 
Arh Hig Rada Toksikol 2020;71:285-299
286Matošević A, Bosak A. Carbamate group as structural motif in drugs: a review of carbamate derivatives used as therapeutic agents Arh Hig Rada Toksikol 2020;71:285-299
Figure 1 Structures of carbamate-based drugs and prodrugs of different application (carbamate group is presented in blue; active 
substance of prodrugs is presented in red)
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feban te lmebendazo le ) ,  and  musc le  re laxan t s 
(methocarbamol, metoxalone) (Figure 1). They also make 
part of prodrugs with different therapeutic applications 
(irinotecan, bambuterol, gabapentin encabril, capecitabine) 
(2, 7, 12) (Figure 1).
The aim of this review is to take a brief look at 
carbamate proprieties that make them useful in drug design, 
discuss some of the carbamate-based drugs and prodrugs, 
and explain the mechanisms of action for some of them.
CARBAMATE PROPERTIES AND 
APPLICATIONS
Chemical properties of carbamates
The structure of biologically active carbamates is shown 
in Figure 2. The carbamate group consists of a carbonyl 
group (C=O) to which an alkoxyl group (OR1 in Figure 2, 
marked blue) and an amino group (R2NR3 in Figure 2, 
marked red) are attached. R1, R2, and R3 may be different 
alkyl, aryl, and alkyl-aryl or substituted alkyl, aryl, and 
alkyl-aryl groups (2, 7). Replacing the carbonyl oxygen 
atom with sulphur generates thiocarbamates, while 
additional replacement of the alkoxy oxygen with a sulphur 
atom generates dithiocarbamates (2).
The carbamate group owes its functionality to the 
structural similarity between amides (R2NR3-CO-R1) and 
carbamates. Namely, carbamates can be structurally 
considered as “amide-ester” hybrids with chemical 
reactivity comparable to these two functional groups. Due 
to this amide-ester combination, carbamates are chemically 
stable and able to modify inter- and intramolecular 
interactions (13).
Carbamate stability stems from the resonance between 
the amide and carboxyl group, which has been studied 
theoretically and experimentally by estimating the C-N 
bond rotational barriers (14). Figure 2 shows three 
resonance structures obtained from carbamate group 
stabilisation. The carbamate rotational barrier of the C-N 
bond is about 3–4 kcal/mol (15–20 %) lower than the 
rotational barrier of structurally analogue amides due to 
steric and electron perturbations which result from the 
presence of additional oxygen of the carboxyl group (14–16) 
and which make carbamates more electrophilic than amides 
and sufficiently reactive to spontaneously react with 
nucleophiles (9).
Another important feature of carbamates is their 
conformation. Due to a pseudo double bond in their 
structure, carbamate molecules can exist as cis and trans 
isomers (Figure 3) (17, 18), but they show no preference 
for either isomeric form, as the difference in free energy of 
the isomers is small, about 1–1.5 kcal/mol due to the steric 
and electrostatic properties of the substituents.
However, this difference in free energy and consequently 
the ratio of the two conformations can change with 
conditions like type and/or composition of the solvents, 
concentration of salts, and pH of the reaction mixture (17, 
18). For example, decreasing the pH of a reaction mixture 
in which amino acids are protected by the tert-butyl 
carbamate (Boc) group, increases the concentration of cis 
isomers, while increasing the temperature increases the 
concentration of trans isomers (19). One study (20) which 
used a carbamate group to connect different ammonium 
groups to the entrance of the gramicidin ion channel, 
demonstrated that the ratio of cis/trans isomers depended 
on combined electrostatic and steric effects of the carbamate 
linker on cation flux through the channel. This suggests that 
a compound able to change the carbamate cis/trans ratio 
may also be used to regulate ion channel flux (13). R and 
R1 (Figure 3) substituents must also be taken into account, 
as the steric effects of R and electronegativity of R1 
influence the difference in free energy and therefore the cis/
trans ratio.
Five-, six-, and seven-membered cyclic carbamates can 
only exist as trans conformers. Five- or six-membered 
carbamates are quite stable because they generally do not 
undergo metabolic ring opening (17).
Furthermore, carbamates are semi-polar compounds 
that can form hydrogen bonds, both as hydrogen donors 
and as hydrogen acceptors, and various interactions can 
take place at their O- and N-termini. Carbamates contain 
C=O and N-C dipoles arising from covalent bonding of 
electronegative oxygen and nitrogen atoms with 
electroneutral carbon atoms. Because of the π-bonding 
arrangement of carbonyl and greater electronegativity of 
oxygen, carbonyl is a stronger dipole than the N-C dipole. 
The presence of a C=O dipole allows carbamates to act as 
H-bond acceptors, whereas the N-C dipole allows them to 
act as H-bond donors, but to a lesser extent (9).
Unlike amides, carbamates are proteolytically stable 
against various proteases (9), and can even inhibit them as 
discussed later. Thanks to these properties – proteolytic, 
chemical, and conformational stability and ability to pass 
through the cell membrane and blood brain barriers (not 
all) – carbamates are increasingly replacing peptides in 
pharmaceuticals (7).
Their pharmacological activity mostly depends on the 
speed and intensity of their hydrolysis (21), and their major 
hydrolysis pathway in physiological conditions is base 
hydrolysis. The mechanisms of base hydrolysis of 
monosubstituted and disubstituted carbamates are shown 
in Figure 4 (22). The difference between these two 
mechanisms is in the intermediate, which is an isocyanate 
anion in monosubstituted carbamates and a carbonate anion 
in disubstituted carbamates. Following basic hydrolysis, 
parent alcohol and carbamic acid are released, and carbamic 
acid rapidly decomposes to the corresponding amine and 
carbon dioxide (21, 22). Carbamate derivatives could be 
used as prodrugs for amines or alcohols and phenols to 
delay first-pass metabolism and enhance hydrolytic stability 
of compounds (23).
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A recent review by Vacondio et al. (21) has compiled 
substantial data from recent studies of metabolic stability 
of therapeutic carbamates to evaluate the qualitative 
relationship between molecular structure of carbamates and 
their susceptibility to metabolic hydrolysis and has proposed 
the following order in metabolic resistance: aryl-OCO-
NHalkyl ˃ ˃ alkyl-OCO-NHalkyl ~alkyl-OCO-N(alkyl)2 ≥ 
alkyl-OCO-N(endocyclic) ≥ aryl-OCO-N(alkyl)2 ~ aryl-
OCO-N(endocyclic) ≥ alkyl-OCONHAryl ~ alkyl-OCO-
NHacyl ˃˃ alkyl-OCO-NH2 > cylclic carbamates (21).
(Cbz), and allyloxycarbonyl (Alloc) (33). As starting 
material, carbamates have also a leading role in the paint 
industry (8, 34).
In recent years, carbamate derivatives, including 
urethanes (especially five- or six-membered cyclic and 
bicyclic fused carbamates) have seen an expansion to 
pharmaceutical industry as important structural and 
functional elements in the design of drugs and prodrugs 
(32, 35).
CARBAMATES AS DRUGS
The biological activity of a carbamate was first reported 
by European missionaries in West Africa in the 19th century. 
There a local tribe was using a white extract from Calabar 
beans (Physostigma venenosum) as an ordeal poison in 
witchcraft trials (36). These beans were imported to Great 
Britain in 1840, and in 1864, Jobst and Hesse isolated an 
active alkaloid component they named physostigmine (37). 
Physostigmine is a naturally occurring methyl carbamate 
ester initially used as a medicine to treat glaucoma, but its 
application broadened over the years. Physostigmine was 
reported to markedly improve muscle strength in patients 
with myasthenia gravis and had been the drug of choice for 
this condition for three decades, until it was replaced by a 
longer-acting oral agent pyridostigmine. Today, 
physostigmine is also used to treat delayed gastric emptying 
and anticholinergic poisoning caused by overdosing with 
atropine, scopolamine, and other anticholinergic drugs. 
Furthermore, pyridostigmine seems to improve long-term 
memory, which is why it was clinically studied for treatment 
of Alzheimer’s disease but was abandoned due to moderate 
to severe side effects in favour of other acetylcholinesterase 
inhibitors (38, 39).
Because of their chemical and proteolytic stability, 
ability to create inter- and intramolecular interactions, and 
bond resembling that of amides, carbamates soon piqued 
the interest of pharmaceutical industry (2, 7, 9). Recent 
studies (2, 8) have shown that incorporating the carbamate 
group in a molecule increases the biological activity of 
active pharmacophores of structurally different natural or 
synthesised compounds. For example, replacing the 
unsaturated ester chain at C-6 in fumagillin (a natural 
antibiotic and endothelial cell proliferation inhibitor) with 
the O-(chloroacetyl) carbamoyl moiety resulted in a 50 
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Figure 2 Possible resonance structures for the carbamate group (amino group is presented in red, and alkoxy group in blue) (adopted 
from ref. 14)
Figure 3 Cis and trans conformations of carbamates (adopted 
from ref. 14)
Application of carbamates
Carbamate derivatives have a wide range of applications. 
Their first massive use in agriculture as pesticides, 
fungicides, and insecticides in various crops all around the 
world started in the 1950s (25–27). They have been the 
second most common pesticides and a welcome replacement 
of poisonous organochloride pesticides since the 1970s. 
Even so, some of them are assumed to be potentially 
carcinogenic and mutagenic or display acute toxicity for 
mammals and aquatic organisms (28–30). Most carbamates 
used in agriculture represent an issue for the environment 
with more than 10,000 tonnes deployed each year, which 
makes their clean-up one of environmental priorities (30).
Mass use of carbamates in everyday life was expanded 
by the discovery of polyurethanes (PUs) – compounds with 
polymerised carbamate groups whose biological, chemical, 
and physical properties enabled carbamate application in 
surface coatings, synthetic fibres, elastomers, foams, and 
packaging (31). It must be mentioned that ethyl carbamate, 
also known as urethane, has no connection with 
polyurethanes in any way. Urethanes are commonly 
synthesised from an alcohol and an isocyanate, while 
carbamate synthesis usually does not involve isocyanate as 
reactant (32).
Carbamates are also used to protect amino groups, most 
notably tert-butoxycarbonyl (Boc), benzyloxycarbonyl 
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times more potent antitumor compound. Another example 
is betulinic acid, a very promising anticancer drug (8), 
whose imidazole and triazole carbamate derivatives were 
12 times more potent and less cytotoxic (2). This possibility 
to change the biological and pharmacokinetic properties 
and improve the stability of parent compounds by varying 
the substituents on the O- and/or N- termini of a carbamate 
group has recently boosted the interest in developing 
efficient and safe synthesis of carbamate esters (8). Today, 
many drugs incorporate the carbamate moiety, whose roles 
in some drugs and prodrugs are listed in Table 1.
Carbamates in tumour treatment
Two carbamate drugs, mitomycin C and docetaxel, have 
so far been approved for the treatment of various types of 
tumours (Figure 1). Both can be used alone or in 
combination to other antitumor drugs (48–50). Their 
antitumor activity stems from their ability to selectively 
inhibit the synthesis of DNA in a tumour cell or to inhibit 
the tubulin polymerisation, both resulting in the arrest of 
mitotic phase of cell division (48).
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Table 1 Roles of the carbamate moiety in drugs and prodrugs
Drug The role of the carbamate moiety in the drug Reference
Docetaxel prolongs drug action, increases drug potency,  improves water solubility 39
Mytomicin C participates in the formation of an alkylating compound during reaction with target 40
Rivastigmine, neostigmine, 
physostigmine, pyridostigmine key element for interaction with the target 38
Ritonavir, amprenavir, atazanavir, 
darunavir
improves drug bioavailability and potency, engaged in a 
backbone interaction with protease 8
Ombitasvir, elbasvir, daclatasavir improves drug stability and lipophilicity 41
Febendazole, mebendazole, febantel, 
albendazole
improves aqueous solubility and bioavailability,  
increases cytotoxicity 42
Mehocarabamol, metaxalone inhibits acetylcholinesterase at synapses in the autonomic nervous system, neuromuscular junction, and central nervous system 43
Felbamate improves drug stability and bioavailability 44, 45
Retigabine major pharmacophore responsible for interacting with residues in the KCNQ2–5 channels 46
Gabapentin enacarbil improves bioavailability 47
Capecitabine improves selectivity and bioavailability 47
Bambuterol delays first-pass metabolism 47
Irinotecan improves aqueous solubility 47
Figure 4 Alkaline hydrolysis of monosubstituted (A) and disubstituted (B) carbamates (adopted from ref. 22)
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Mitomycin C is a miscellaneous antibiotic that 
selectively inhibits DNA synthesis in a tumour cell and is 
indicated for chemotherapy of gastrointestinal, anal, and 
breast cancers (49). Its mechanism of action is given in 
detail in Figure 5 (40). All starts with an in situ bioreductive 
activation of quinone that involves two consecutive 
reduction steps to the corresponding hydroquinone. The 
elimination of methanol from hydroquinone produces a 
reactive imine. Deprotonation of imine results in an indole 
derivative that undergoes rearrangement to produce a 
quinone methide, which then reacts with nucleophilic DNA 
groups, yielding an unstable intermediate that binds to 
complementary strands of double-stranded DNA coils. This 
binding inhibits DNA replication and causes tumour cell 
death. At high concentrations, mitomycin C has also been 
shown to suppress RNA and protein synthesis, inhibit 
proliferation of B-cells, T-cells, and macrophages in vitro, 
and to reduce the secretion of interferon gamma, tumour 
necrosis factor alpha (TNFα), and interleukin 2 (IL-2) (40, 
51).
Docetaxel (Figure 1) is a chemotherapeutic used to treat 
breast, head/neck, stomach, prostate, and lung cancers. It 
binds to the β-subunit of tubulin and forms the docetaxel-
tubulin complex, which interferes with tubulin 
polymerisation and, in turn, leads to tumour cell cycle arrest 
and apoptosis, including the apoptosis of B-cells affected 
by leukaemia (50, 52).
Carbamates in HIV infection treatment
HIV-1 protease is essential for viral maturation, as it 
cleaves newly synthesised polyproteins Gag and Gag-Po 
to create mature protein components of the HIV virion, the 
infectious form of the virus outside the host cell (53). There 
are ten HIV protease inhibitors approved by the FDA, four 
of which have the carbamate group in their structure 
(ritonavir, atazanavir, amprenavir, and darunavir). These 
bind directly to the active site of HIV-1 protease to prevent 
Gag and Gag-Po cleavage (53–58). One of them, ritonavir, 
was later found that not only it inhibits HIV protease but 
can also boost blood concentrations of other HIV protease 
inhibitors by inhibiting cytochrome P450 3A4, which would 
otherwise metabolise them and render inefficient (54–56). 
Another HIV protease inhibitor, atazanavir, shows good 
oral bioavailability allowing a once-a-day dosing. It is used 
only in combination with ritonavir and/or other antiviral 
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Figure 5 Mechanism of action of mitomycin C (adopted from ref. 40)
Figure 6 Proposed targets and mechanism of action of felbamate and retigabine in postsynaptic neuron (adopted from refs. 62 and 63)
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Figure 7 A proposed simplified mechanism for AChE inhibition by carbamates. Rapid formation of the covalent enzyme-carbamate intermediates, 
followed by slow regeneration of a free AChE prevents breaking down of acetylcholine in postsynaptic cleft by AChE (adopted from ref. 81)
drugs (55, 56) and as such currently makes the first-line 
antiretroviral treatment (56, 57).
Carbamates as antiepileptics and anticonvulsants
Carbamate anticonvulsants used in epilepsy treatment 
are felbamate and retigabine (Figure 1). Their exact 
mechanism of action is still unclear but what is known is 
that they inhibit N-methyl-D-aspartate (NMDA) receptors 
to some extent and slightly enhance gamma-aminobutyric 
acid (GABA) activity (59, 60).
Felbamate is potent and very effective anticonvulsant 
approved by FDA in 1993 for the management of focal 
seizures and Lennox-Gastaut syndrome. It is effective as 
monotherapy or add-on to phenytoin and carbamazepine in 
patients with uncontrolled focal epilepsy (61, 62). However, 
its approval has now been limited because its use is 
associated with the development of aplastic anaemia and 
hepatic failure. It is now available in the USA only for a 
very limited use, principally by neurologists in patients for 
whom potential benefit outweighs the risk (60). It is believed 
that felbamate acts as NMDA receptor-ionophore complex 
antagonist at the strychnine-insensitive glycine-recognition 
site (62), as it blocks the effects of excitatory amino acids, 
suppresses neuronal firing, and prevents seizure. As for 
GABA receptors, some studies suggest that felbamate 
weakly inhibits GABAA-receptor binding sites and thus 
enhances GABA-elicited Cl- currents in cultured cortical 
neurons. This may explain how felbamate dampens 
neuronal excitation and inhibits voltage-gated sodium and 
calcium channels (Figure 6) producing a barbiturate-like 
effect (63, 64). However, one in vitro receptor-binding study 
reported that felbamate did not enhance GABA evoked 
36Cl- influx in cultured spinal cord neurons (65). These 
discrepancies between reports may lie in varying regional 
and ontogenetic expression of GABA receptor subunits and 
varying properties of GABA receptors between central 
nervous system (CNS) regions and stages of development 
(66).
Retigabine is an anticonvulsant used as adjunct in the 
treatment of partial seizures in adult patients, tinnitus, 
migraine, and neuropathic pain (45, 46, 67). The mechanism 
of its action is unique among antiepileptic drugs and 
represents a new approach in the treatment of neurological 
conditions. Retigabine works primarily by opening a 
particular group of voltage-regulated potassium ion 
channels in brain cells – KCNQ2 and KCNQ3 (Figure 6) 
– which stabilises the resting membrane potential and 
regulates electrical neuron excitation to keep it below the 
threshold. This prevents the onset of epileptiform discharges 
(46, 67, 68).
Cenobamate is indicated for the treatment of partial-
onset seizures in adults (3, 4). It selectively blocks the 
persistent sodium current of voltage-gated sodium channels 
(VGSCs) (3, 4). It also acts as a positive allosteric modulator 
of high-affinity GABAA receptors to stabilise neural circuits 
of the epileptic hippocampus (69).
Carbamates in the treatment of neurodegenerative 
diseases
Neurodegenerative diseases are characterised by 
progressive structural and functional degeneration of the 
central and/or peripheral nervous system (70). One of their 
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clinical manifestations is the depletion of acetylcholine 
(ACh), a neurotransmitter in cholinergic synapses, caused 
by its excessive metabolism to choline and acetic acid 
mediated by cholinesterases. In humans, there are two 
cholinesterases: acetylcholinesterase (AChE), whose 
phys io logica l  ro le  i s  to  hydrolyse  ACh,  and 
butyrylcholinesterase (BChE), whose physiological role is 
still unclear, except that it hydrolyses ACh and other esters 
and scavenges some toxins by reacting with them before 
they reach AChE (70–72). Treatment of patients with 
neurodegenerative diseases who have low ACh levels 
(Alzheimer’s disease) and disorders of the neuromuscular 
system (Parkinson’s disease, myasthenia gravis) is focused 
on alleviating symptoms. Restoring the concentration of 
ACh by inhibiting AChE (Figure 7) is the primary treatment 
for cognitive deficits, although more recent studies point to 
BChE as a new possible target of cholinesterase inhibitors 
(73–75). To date, different types of cholinesterase inhibitors 
have been identified, designed, and synthesised. The first 
such cholinesterase inhibitor to be clinically approved was 
a natural carbamate physostigmine (76). Since then, many 
carbamates have been developed and tested for the treatment 
of various disorders of cholinergic neurotransmission. Four 
of them are currently approved for treating neurodegenerative 
diseases: physostigmine, pyridostigmine, rivastigmine, and 
neostigmine (Figure 1) (77).
Physostigmine acts by inhibiting AChE activity and 
preventing ACh hydrolysis, which in turn increases ACh 
levels at the synapse and indirectly stimulates nicotinic and 
muscarinic receptors. As it crosses the blood-brain barrier, 
it can also treat the effects of atropine and other 
anticholinergic drug overdoses on the CNS (78, 79).
P y r i d o s t i g m i n e  a n d  n e o s t i g m i n e  a r e 
parasympathomimetics used in the treatment of myasthenia 
gravis and both inhibit AChE (78, 80). Rivastigmine inhibits 
both AChE and BChE and is used to treat mild to moderate 
Alzheimer’s and Parkinson’s dementia (77).
Cymserine is a physostigmine-based compound with a 
isopropylphenyl instead of a methyl group at the N-4’ 
position, which makes it 15 times more selective for BChE 
than AChE (81–84). In clinical trials it has shown highly 
promising results in patients with Alzheimer’s disease, but 
also unacceptable side effects caused by its toxic metabolites 
(85).
One of the pathological features of Alzheimer’s is the 
formation of β-amyloid (Aβ) peptides in the cortex of 
patients with Alzheimer’s. Aβ-peptides are generated by 
sequential cleavage of β-amyloid precursor protein (APP) 
by β-secretase and γ-secretase. These two enzymes have 
therefore become important targets in designing drugs to 
treat Alzheimer’s disease (8).To overcome the limitations 
imposed by cymserine metabolite induced side effects in 
clinical trials, several cymserine derivatives (Figure 8) have 
been tested in vivo and shown to increase ACh levels in the 
brain, produce nootropic effects, and reduce APP and Aβ-
peptide levels. They have the potential to become the first 
drugs capable of stopping and even reversing the 
progression of Alzheimer’s disease (86).
Many other carbamate compounds have been designed 
as potential secretase inhibitors, but none have yet been 
approved for medical use. Some have shown great 
β-secretase inhibition potential, like the 16-membered 
macrocycle (compound A in Figure 9) containing a trans-
olefin, amide, and carbamate functionalities. Others, like 
Figure 8 Cymserine and its derivatives (carbamate group in blue) (adopted from ref. 82)
Figure 9 Chemical structure of secretase inhibitors tested with potential to be used in treatment of Alzheimer’s disease A – a 16-membered 
macrocycle compound; B – sulphonamide compound (adopted from ref. 8)
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sulphonamide derivatives (B in Figure 9) have shown strong 
γ-secretase inhibition (8).
Carbamates in the treatment of hepatitis C
Hepatitis C virus (HCV) causes acute and chronic mild 
to severe hepatitis. With time, a significant number of 
chronic patients develop cirrhosis or liver cancer (87).
Recent years have seen the development of a number of 
new and effective hepatitis C drugs which specifically target 
viral NS3/4A protease, non-structural protein 5A (NS5A), or 
NS5A RNA polymerase to inhibit viral replication, and counter 
NS5A-associated interferon-resistance as the common cause 
of treatment failure (87–89). Today, there are ten carbamates 
targeting NS5A. Six have been approved for use (89) and the 
rest are in phase III of clinical trials (89, 90). They inhibit NS5A 
by blocking signalling interactions, redistributing NS5A from 
the endoplasmic reticulum to the surface of lipid droplets, and 
by inhibiting HCV replication (9, 92). Figure 1 shows the 
structures of three approved carbamate HCV inhibitors: 
daclatasavir, elbasvir, and ombitsavir (93).
Antiviral action is further increased by combining NS5A 
with NS3/4A protease inhibitors, as is the case with daclatasavir 
and sofosbuvir (92–95). Both daclatasavir and sofosbuvir and 
their combination have been included in the WHO model list 
of the most efficacious, safe, and cost-effective medicines for 
a specific condition, the so called essential medicines list 
(EML) (96).
Carbamates as muscle relaxants
The best known carbamate muscle relaxants are 
methocarbamol and metaxalon (Figure 1) (43). Although the 
exact mechanism of action of methocarbamol is still not 
clarified, it is believed to involve AChE inhibition at synapses 
in the autonomic nervous system, neuromuscular junction, and 
the CNS (97). Metaxalone is usually prescribed as adjuvant 
therapy that accompanies rest, physical therapy, and other 
measures to relieve acute musculoskeletal pain. Its mode of 
action is also not clear, but is most likely related to general 
CNS depression (98).
Carbamates as anthelmintics
The carbamates that act against parasitic worms or 
helminths in humans and animals are fenbendazole, 
febantel, mebendazole, and albendazole (Figure 1) (99). 
Mebendazole and albendazole are benzimidazole carbamate 
anthelmintics used to treat a broad range of parasitic 
infections (100, 101). Their mechanism of action is 
analogous to that of docetaxel: they selectively inhibit 
microtubule synthesis by binding to β-tubulin and blocking 
the polymerisation of tubulin dimers in intestinal parasite 
cells. This disruption of cytoplasmic microtubules results 
in blocking glucose and other nutrient transport in parasites 
cells and their gradual immobilisation and death (101).
CARBAMATES AS PRODRUGS
Prodrugs are designed to undergo enzymatic and/or 
chemical metabolism in the body to release the active drug 
with a desired pharmacological effect (Figure 10) (47, 102). 
They serve as carriers to overcome physicochemical, 
biopharmaceutical, or pharmacokinetic limitations of active 
drugs by increasing their solubility in water and absorption, 
by delaying their first-pass metabolism, by delivering them 
to the brain, or by reducing their toxicity and local irritation 
(103). Prodrugs generally consist of a parent (active) drug 
and a promoiety that masks the functional group within the 
parent drug (Figure 10). Typically, a promoiety is attached 
to the active drug with bond(s) that break in certain 
conditions, such as the presence of an enzyme or a change 
in pH and releasing the active substance to do its job (103). 
Esters are used as prodrugs to improve lipophilicity and 
permeability through cell membranes, while phosphate 
esters, oximes, and amides are used to improve drug 
solubility in water and oral absorption (47, 103).
Carbamates are used in the design of prodrugs of 
carboxyl, hydroxyl, or amine functionalities to delay first-
pass metabolism and enhance systemic hydrolytic stability 
(103) (Table 1). Their bioconversion for active drug release 
involves rapid hydrolysis mediated by metabolic enzymes, 
mainly cytochrome P450 and esterases, which usually 
occurs in the liver (22, 47,103).
Carbamate prodrugs with a phenol as active substance
Carbamates are used as prodrugs of alcohols and 
phenols to achieve systemic hydrolytic stability and 
protection from first-pass metabolism (23). Carbamates of 
N-monosubstituted and N, N-disubstituted alcohols are 
chemically stable against hydrolysis (21), as are the 
carbamates of N, N-disubstituted phenols but not as much 
those of N-monosubstituted phenols (21, 24). Examples of 
carbamate prodrugs whose active substance is alcohol or 
phenol are irinotecan and bambuterol (Figure 1).
Figure 10 A simplified illustration of the prodrug concept
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Irinotecan (CPT-11) is a semisynthetic analogue of the 
natural alkaloid camptothecin, commonly used for the 
treatment of colon, rectal, and ovarian cancers (104, 105). 
In human body, irinotecan is metabolised by tissue and 
serum carboxylesterases to an active compound SN-38 
(106), which has a 100–1,000 times higher antitumour 
activity than irinotecan. SN-38 inhibits topoisomerase I 
activity by stabilising the cleavable complex between 
topoisomerase I and DNA, which leads to DNA breaks, 
inhibition of DNA replication, and triggers apoptotic cell 
death (Figure 11) (106).
Bambuterol (Figure 1) is a bis-dimethyl carbamate 
prodrug of terbutaline, used to treat asthma and chronic 
obstructive pulmonary disease. Bambuterol belongs to 
long-acting drugs due to catecholic hydroxyl groups in its 
structure that are quite resistant to hydrolysis and first-pass 
metabolism. In the lung tissue, bambuterol is hydrolysed 
to terbutaline by BChE (Figure 12), and in the liver, it is 
metabolised to terbutaline under the influence of cytochrome 
P-450-dependent oxidases (24, 107, 109). Terbutaline is an 
adrenergic agonist that predominantly stimulates ß-2 
receptors to relax the smooth muscle of the bronchus and 
dilate the airways (107–109).
Carbamate prodrugs with an amine as active substance
At physiological pH amine-based drugs or drugs having 
an amine group in the structure can undergo protonation 
and may not always be optimally distributed in the body 
(47, 102). Because of that, polar amino groups are often 
derivatised to make the compounds neutral or hydrophobic, 
i.e. more soluble in lipids (47, 102). One of the derivatisation 
strategies involves introduction of carbamate moiety into 
drug structure. Currently used amine-based carbamate 
Figure 12 Bambuterol metabolism into tertbutaline by cytochrome p450 and butyrylcholinesterase (BChE) (adopted from ref. 106)
Matošević A, Bosak A. Carbamate group as structural motif in drugs: a review of carbamate derivatives used as therapeutic agents 
Arh Hig Rada Toksikol 2020;71:285-299
Figure 11 Irinotecan metabolism by carboxylesterases hCE-1 and hCE-2 (adopted from ref. 105)
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prodrugs gabapentin enacarbil and capecitabine are 
presented in Figure 1.
Gabapentin enacarbil is a prodrug designed to increase 
oral bioavailability of gabapentin used to treat the restless 
legs syndrome (RLS) and postherpetic neuralgia (PHN) in 
adults (110). After oral administration gabapentin enacarbil 
gets strongly hydrolysed by non-specific carboxylesterases, 
primarily in enterocytes and to a lesser extent in the liver, 
to form the active drug gabapentin, carbon dioxide, 
acetaldehyde, and isobutyric acid (110).
Capecitabine is a fluoropyrimidine carbamate of the 
antimetabolite class of chemotherapeutics (111) that is 
selectively activated by tumour cells to produce cytotoxic 
5-fluorouracil (5-FU) (112), which is then metabolised to 
its active components 5-fluoro-2-deoxyuridine 
monophosphate  (FdUMP) and 5-fluorouridine 
triphosphate (FUTP). The first inhibits DNA synthesis and 
cell division by reducing normal thymidine production, 
and the second inhibits RNA and protein synthesis by 
competing with uridine triphosphate for incorporation into 
the RNA strand (111, 112).
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Karbamatna skupina kao strukturni element lijekova – pregledni rad
Zbog svoje vrlo dobre kemijske i proteolitičke stabilnosti, sposobnosti prodiranja kroz stanične membrane i sličnosti s 
peptidnom vezom, derivati karbamata posljednjih godina sve više privlače pozornost medicinskih kemičara i dobivaju 
važniju ulogu u modernom načinu otkrivanja lijekova. Tako je u današnje vrijeme karbamatna skupina strukturni i 
funkcionalni element mnogih odobrenih lijekova, a mnogi se već i koriste kao lijekovi za liječenje raznih vrsta bolesti 
poput raka, epilepsije, hepatitisa C, infekcije HIV-om, Alzheimerove bolesti i mnogih drugih. U lijekovima, karbamatna 
skupina može biti važan dio molekule koji ima ulogu u interakciji lijek-meta ili je umetnuta u strukturu spoja kako bi se 
poboljšala biološka aktivnost temeljne molekule. U protulijekovima, karbamatna se skupina koristi uglavnom zbog 
mogućnosti smanjenja osjetljivosti spoja na metaboličke enzime, odnosno povećanja hidrolitičke stabilnosti samoga spoja. 
U ovom je radu dan ne samo kratki pregled karbamata koji se koriste kao lijekovi u raznim područjima primjene, kao i 
karbamata koji se koriste kao protulijekovi, nego i uvid u mehanizam djelovanja nekih od njih.
KLJUČNE RIJEČI: antiepileptici; antikonvulzanti; inhibitori kolinesteraza; inhibitori proteaza; neurodegenerativne 
bolesti; protulijekovi
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